Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review

Genomic profiling and precision medicine in complex ameloblastoma

(2023) James C. Gates et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type

(2022) Kyu‐Young Oh et al.   GENES CHROMOSOMES & CANCER

Phase I study of the irreversible FGFR1 ‐4 inhibitor futibatinib in Japanese patients with advanced solid tumors

(2022) Toshihiko Doi et al.   CANCER SCIENCE

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2021) James M. Cleary et al.   CLINICAL CANCER RESEARCH

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

(2021) Golnaz Morad et al.   CELL

Autophagy and immune microenvironment in craniopharyngioma and ameloblastoma

(2021) Georgia Karpathiou et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration

(2021) Ariel Hirschhorn et al.   Journal of Tissue Engineering and Regenerative Medicine

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

(2020) April K. S. Salama et al.   JOURNAL OF CLINICAL ONCOLOGY

Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies

(2020) Hongyi Adrian Shi et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: clinicopathological significance and correlation with epithelial‐mesenchymal transition

(2019) Kyu‐Young Oh et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma

(2019) Maxime Brunet et al.   Frontiers in Oncology

Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms

(2018) Stephan Bartels et al.   VIRCHOWS ARCHIV

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

(2018) Gustavo S. Fernandes et al.   BMC CANCER

The Mutational Profile of Unicystic Ameloblastoma

(2018) K. Heikinheimo et al.   JOURNAL OF DENTAL RESEARCH

COSMIC: the Catalogue Of Somatic Mutations In Cancer

(2018) John G Tate et al.   NUCLEIC ACIDS RESEARCH

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma

(2016) Daniel L Faden et al.   JNCI-Journal of the National Cancer Institute

BRAF inhibitor treatment of primary BRAF -mutant ameloblastoma with pathologic assessment of response

(2016) Serena Tan et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma

(2016) Daniel L Faden et al.   JNCI-Journal of the National Cancer Institute

Activating FGFR2-RAS-BRAF Mutations in Ameloblastoma

(2014) N. A. Brown et al.   CLINICAL CANCER RESEARCH

Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma

(2014) F. J. Kaye et al.   JNCI-Journal of the National Cancer Institute

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER